Middle East and Turkey Hemophilia Treatment Market Analysis| Coherent Market Insights

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. MIDDLE EAST AND TURKEY HEMOPHILIA TREATMENT MARKET ANALYSIS Middle East and Turkey Hemophilia Treatment Market, by Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Country (Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East) - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027.

3. Market Insights Hemophilia is treated with recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Most of the patients with hemophilia prefer factor replacement therapy as primary treatment, owing to its positive outcomes. Increasing approval and launches of recombinant coagulation factor in the Middle East region are expected to drive growth of the recombinant coagulation factor segment in Middle East and Turkey hemophilia treatment market. For instance, in October 2017, Swedish Orphan Biovitrum AB (publ) received approval for its Alprolix (eftrenonacogalfa, Coagulation Factor IX (Recombinant), for the treatment of hemophilia B, from Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia.

4. The Middle East and Turkey hemophilia treatment market is estimated to be valued at US$ 645.1 million in 2019, and is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027). Market Growth • Increasing product approvals by the key players is expected to drive the market growth over the forecast period. For instance, in August 2018, Bayer AG, received the U.S. Food and Drug Administration approval for its new hemophilia A treatment product, Jivi with flexible dosing regimen. It is used for the treatment of bleeding in adults and adolescents (12 years of age and above), who were previously treated for hemophilia A. Moreover, in February 2018, Shire Plc , the local branch of the global biotech pharmaceutical Shire, received approval from the Ministry of Food and Drug Safety for Adynovate, a long-lasting factor VIII gene recombinant for hemophilia A treatment.

5. Furthermore, key players are focused on adopting growth strategies such as acquisitions that is expected to drive the Middle East and Turkey hemophilia treatment market growth over the forecast period. For instance, in April 2014, Baxter International Inc. acquired Chatham Therapeutics, LLC, a privately held clinical development-stage biotechnology company engaged in development of novel, gene therapy-mediated treatments for hemophilia. Baxter acquired Chatham's developmental gene therapy platform to facilitate development and commercialization of hemophiliatreatment.

6. Figure 1.Middle East and Turkey Hemophilia Treatment Market Share (%), By Product Type, (2019 & 2027)

7. Market Restraints High cost of treatment for hemophilia is a major factor, which is expected to hinder the market growth over the forecast period.Hemophiliais associated with high aggregate costs and imposes a high financial burden on individuals,andhealthcare systems in emerging economies.Hemophiliais a chronic condition that requires lifelong treatment,withindividual costs varying based on disease severity,complications and treatment regimen.Forinstance,accordingto a cohort study conducted by National Center for Biotechnology Information (NCBI) in 2015,hemophilia treatment is expensive,particularlyfor patients with severe hemophilia.Accordingto the study,severehemophilia is associated with greater annual costs in both types of hemophilia.

8. For instance,according to the study NCBI in 2015,the annual cost required for the treatment of hemophilia A is around US$ 84,766.9 and hemophilia B is around US$ 122,877.Patients with factor VIII inhibitors have costs 3.3 times higher than patients without factor VIII inhibitors.Thus, high cost of therapy is expected to hinder the market growth over the forecast period.

9. Figure 2.Middle East and Turkey Hemophilia Treatment Market Share (%), By Country, (2019 & 2027)

10. Regional Analysis • Country wise segmentation of the Middle East and Turkey Hemophilia Treatment Market include Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East. • Among countries, Turkey is expected to witness a significant growth in the Middle East and Turkey hemophilia treatment market over the forecast period, owing to availability of the hemophilia drugs and increasing patient population are expected to propel the market growth in Turkey over the forecast period. For instance, Baxalta Incorporated produced ADYNOVATE, an antihemophilic recombinant factor indicated for the patients above 12 years suffering from Hemophilia A. It is available in Turkey and other 66 countries, globally.

11. Furthermore, rising support of market players and government organizations in providing access to hemophilia drugs for people is expected to fuel the market growth in Egypt over the forecast period. For instance, In November 2017, Octapharma AG, in collaboration with Project SHARE, donated 30.5 million units of human cell-line derived recombinant factor VIII product, Nuwiq, for the treatment of patients with hemophilia A in emerging economies such as Bangladesh, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Myanmar, Nepal, and others.

12. Competitive Section Key players operating in the Middle East and Turkey hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and  Spark Therapeutics, Inc.

13. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/middle-east-and-turkey-hemophilia-treatment-market-3250

14. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

15. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

16. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/